Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

Fokas, Emmanouil; Prevo, Remko; R. Pollard, John; M. Reaper, Philip; Charlton, Peter; Cornelissen, Bart; A. Vallis, Katherine; M. Hammond, Ester; M. Olcina, Monica; Gillies McKenna, W.; J. Muschel, Ruth; Brunner, Thomas

doi:10.1038/cddis.2012.181

Public

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

Published in Cell Death and Disease • Dec 6, 2012

Authors:

Emmanouil Fokas

Remko Prevo

John R. Pollard

Abstract

Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiat...

Subject

Pancreatic cancer

Gemcitabine

In vivo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!